

COMMUNIQUÉ FROM EXTRAORDINARY GENERAL MEETING IN PROSTATYPE GENOMICS AB (PUBL) HELD ON 16 JULY 2024

Prostatype Genomics AB (publ) reg.no 556726-0285 (the "Company"), listed on the Nasdaq First North Growth Market, held an extraordinary general meeting today on 16 July 2024, whereby the following resolutions were made.

In accordance with previously published information, the board of directors resolved on 13 June 2024, subject to the subsequent approval of the extraordinary general meeting, on a preferential rights issue of not more than 990,811,186 units, corresponding to a maximum of 4,954,055,930 shares and 1,981,622,372 warrants of series TO 4. The general meeting has today, with the required majority, resolved to approve the board of director's resolution on the preferential rights issue. In order to enable the implementation of the aforementioned rights issue, the meeting also approved the board of director's proposal to change the articles of association by increasing the intervals for share capital and number of shares.

The decision entails an increase of the share capital by not more than SEK 69,356,783.02 and can initially, should the preferential rights issue be fully subscribed, add approximately SEK 49.5 million to Prostatype Genomics AB before issue costs. Shares must be subscribed during the period from 19 August 2024 to 2 September 2024.

The meeting also resolved to approve the board of director's proposal to authorize the board to, on one or more occasions during the time until the next annual general meeting, resolve to increase the company's share capital within the limits of the articles of association by issuing shares and/or warrants. The authorization may only be used to issue units to those who acted as guarantors in the above-mentioned issue.

All resolutions at the meeting were adopted unanimously.

Contacts

For further information about Prostatype Genomics, please contact:

Fredrik Rickman (previously Persson), CEO Prostatype Genomics AB

Telephone: +46 (0) 73 049 77 01.

e-mail: fredrik.persson@prostatypegenomics.com

Certified Advisor

Carnegie Investment Bank AB (publ), +46 (0)73 856 42 65, certifiedadviser@carnegie.se

About Us

About Prostatype Genomics AB

Prostatype® is a genetic test that is available to patients and treating urologists as a supplementary decision support tool to answer the question of radical treatment or no radical treatment of prostate cancer. The test is developed by a research group at Karolinska Institutet and is provided by Prostatype Genomics AB.